Literature DB >> 19719464

Costing of severe pneumonia in hospitalized infants and children aged 2-36 months, at a secondary and tertiary level hospital of a not-for-profit organization.

Helle Ostergaard Madsen1, Malin Hanehøj, Ashima Rani Das, Prabhakar D Moses, Winsley Rose, Mammen Puliyel, Flemming Konradsen, K R John, Anuradha Bose.   

Abstract

OBJECTIVES: To determine health care provider cost and household cost of the treatment of severe pneumonia in infants and young children admitted to secondary and tertiary level health care facilities.
METHODS: The study was done in a private, not-for-profit medical college hospital, in Vellore, India, in mid-2008. Children aged 2-36 months admitted with severe pneumonia with no underlying chronic disease were included in the study. The relatives were interviewed daily on matters relating to patients' view point of the costs. These were direct medical costs, direct non-medical costs which comprised travel, accommodation and special food during the period of illness, and indirect costs of productivity loss for family members. Patient specific resource consumption and related charges were recorded from charts, nursing records, pharmacy lists and hospital bills, and the providers view point of the costs was estimated. Unit cost estimates for bed days, treatment and investigation inputs were calculated.
RESULTS: Total cost to health care provider for one episode of hospitalized childhood pneumonia treated at secondary level was US$ 83.89 (INR 3524) and US$ 146.59 (INR 6158) at tertiary level. At both levels the greatest single cost was the hospital stay itself, comprising 74% and 56% of the total cost, respectively. Diagnostic investigations were a large expense and supportive treatment with nebulization and oxygen therapy added to the costs. Mean household expenditure on secondary level was US$ 41.35 (INR 1737) and at tertiary level was US$ 134.62 (INR 5655), the largest single expense being medicines in the former and the hospitalization in the latter. (one US$=INR 42.1 at time of study)
CONCLUSIONS: A considerable cost difference exists between secondary and tertiary level treatment. Admission at lowest possible treatment level for appropriate patients could decrease the costs borne by the provider and the patient.

Entities:  

Mesh:

Year:  2009        PMID: 19719464     DOI: 10.1111/j.1365-3156.2009.02374.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  23 in total

1.  Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants.

Authors:  Ulla Kou Griffiths; Andrew Clark; Rana Hajjeh
Journal:  J Pediatr       Date:  2013-07       Impact factor: 4.406

2.  Cost of Treatment of Febrile Acute Respiratory Infection (FARI) Among Under-Five Children Attending Health Facilities of Ballabgarh, Haryana.

Authors:  Debjani Ram Purakayastha; Sanjay Kumar Rai; Shobha Broor; Anand Krishnan
Journal:  Indian J Pediatr       Date:  2017-08-23       Impact factor: 1.967

3.  Household Costs Associated with Hospitalization of Children with Severe Pneumonia in Quito, Ecuador.

Authors:  Lora L Sabin; Bertha Estrella; Fernando Sempértegui; Norman Farquhar; Aldina Mesic; Nafisa Halim; Chia-Ying Lin; Oswaldo Rodriguez; Davidson H Hamer
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

4.  Treatment costs of pneumonia, meningitis, sepsis, and other diseases among hospitalized children in Viet Nam.

Authors:  Dang Duc Anh; Arthorn Riewpaiboon; Le Huu Tho; Soon Ae Kim; Batmunkh Nyambat; Paul Kilgore
Journal:  J Health Popul Nutr       Date:  2010-10       Impact factor: 2.000

5.  Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India.

Authors:  Andrew D Clark; Ulla K Griffiths; Syed Shahid Abbas; Krishna D Rao; Lois Privor-Dumm; Rana Hajjeh; Hope Johnson; Colin Sanderson; Mathuram Santosham
Journal:  J Pediatr       Date:  2013-07       Impact factor: 4.406

6.  Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.

Authors:  Itamar Megiddo; Eili Klein; Ramanan Laxminarayan
Journal:  BMJ Glob Health       Date:  2018-05-09

7.  Household economic burden of childhood severe pneumonia in Bangladesh: a cost-of-illness study.

Authors:  Marufa Sultana; Nur H Alam; Nausad Ali; A S G Faruque; George J Fuchs; Niklaus Gyr; Md Jobayer Chisti; Tahmeed Ahmed; Lisa Gold
Journal:  Arch Dis Child       Date:  2021-04-27       Impact factor: 3.791

8.  Revisiting community case management of childhood pneumonia: perceptions of caregivers and grass root health providers in Uttar Pradesh and Bihar, northern India.

Authors:  Shally Awasthi; Mark Nichter; Tuhina Verma; Neeraj Mohan Srivastava; Monica Agarwal; Jai Vir Singh
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

9.  Time to Recovery from Severe Pneumonia and Its Predictors Among Children 2-59 Months of Age Admitted to Pediatric Ward of Nigist Eleni Mohammed Memorial Comprehensive Specialized Hospital, Hossana, Ethiopia: Retrospective Cohort Study.

Authors:  Lire Lemma Tirore; Desta Erkalo Abame; Tagesse Sedoro; Dejene Ermias; Abinet Arega; Tegegn Tadesse; Selamu Abose Nadamo
Journal:  Pediatric Health Med Ther       Date:  2021-07-21

10.  Household costs for treatment of severe pneumonia in Pakistan.

Authors:  Salim Sadruddin; Shafqat Shehzad; Abdul Bari; Attaullah Khan; Amanullah Khan; Shamim Qazi
Journal:  Am J Trop Med Hyg       Date:  2012-11       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.